Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
B7-33 (Relaxin Mimetic)
Preclinical
Research chemical
Summary
Single-chain H2-relaxin B-chain derivative that preferentially activates antifibrotic RXFP1–pERK signaling; retains organ antifibrosis benefits of serelaxin without full cAMP profile in key models.
Categories
Healing & Recovery, Longevity
Mechanism
Functionally selective RXFP1 agonism biased toward pERK and antifibrotic MMP pathways; may engage RXFP1–AT2 receptor heterodimer signaling relevant to collagen degradation. Short serum half-life (~minutes) with lipidated analogs under study for longer PK.
Half-life
~6 minutes in serum (unmodified); lipidated analogs longer
Routes
Subcutaneous injection
Legal / access
Experimental antifibrotic research peptide. Not approved therapy.
Key risks
- Unknown human adverse profile
- Short half-life may limit practicality
Common claims
- Antifibrotic recovery
- Heart and lung remodeling
- Safer relaxin alternative narratives
Select peptide B